Macular edema Macular edema Macular edema occurs when fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken and swell (edema). The swelling may distort a person's central vision, because the macula holds tightly packed cones that provide sharp, clear, central vision to enable a person to see detail, form, and color that is directly in the centre of the field of view. The causes of macular edema are numerous and different causes may be inter-related. Cystoid macular edema (CME) involves fluid accumulation in the outer plexiform
Macular edema with NSAID or cortisone eye drops. Prophylactic use of Nonsteroidal anti-inflammatory drugs has been reported to reduce the risk of macular edema to some extent. In 2010 the US FDA approved the use of Lucentis intravitreal injections for macular edema. Iluvien, a sustained release intravitreal implant developed by Alimera Sciences, has been approved in Austria, Portugal and the U.K. for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. Additional EU country approvals are anticipated. In 2013 Lucentis by intravitreal injection was approved by the National Institute for Health and Care